Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

UK secures two million more doses of Moderna's COVID-19 vaccine

11/29/2020 | 07:42am EST
FILE PHOTO: Vials and medical syringe are seen in front of Moderna logo in this illustration

(Reuters) - Britain has secured two million doses of Moderna Inc's COVID-19 vaccine candidate, to be available in Europe as early as the spring, the government said on Sunday, in addition to the 5 million doses it secured from the U.S. company two weeks ago.

The new deal came a day after Prime Minister Boris Johnson named Nadhim Zahawi, a junior business minister, to be minister responsible for the deployment of COVID-19 vaccines.

Britain now has access to enough doses of Moderna's vaccine candidate for around 3.5 million people. Overall, it has access to 357 million doses of vaccines from seven developers, according to government statement.

"With a wide range of vaccine candidates in our portfolio, we stand ready to deploy a vaccine should they receive approval from our medicines regulator, starting with those who will benefit most," health minister Matt Hancock said in the statement.

Moderna's experimental vaccine is 94.5% effective in preventing COVID-19 based on interim data from a late-stage trial.

Deliveries to Britain could begin as early as the spring, if the vaccine meets the standards of the Medicines and Healthcare products Regulatory Agency.

Britain has also ordered 40 million doses of a vaccine developed by Germany's BioNTech SE and Pfizer Inc of the United States, which has been found to be 95% effective in preventing the spread of the new coronavirus.

The UK regulator is set to approve the BioNTech-Pfizer vaccine this week, and deliveries will begin within hours of the authorisation, the Financial Times said on Saturday.

Britain has also secured 100 million doses of the vaccine developed by AstraZeneca PLC and Oxford University and has targeted a rollout to begin before Christmas.

(Reporting by Radhika Anilkumar in Bengaluru; Additional reporting by Maria Ponnezhath in Bengaluru; Editing by Himani Sarkar and William Mallard)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.66% 7777 Delayed Quote.6.19%
BIONTECH SE 2.86% 108.44 Delayed Quote.33.02%
MODERNA, INC. -1.47% 131.02 Delayed Quote.25.41%
PFIZER INC. 0.19% 36.55 Delayed Quote.-0.71%
All news about MODERNA, INC.
01/22PFIZER : Provinces doing 'extraordinary' job to avoid wasting doses of COVID-19 ..
AQ
01/2239.9 MLN DOSES OF COVID-19 VACCINES : U.s. cdc
RE
01/22CDC : 10 life-threatening reactions linked with Moderna COVID-19 vaccine
AQ
01/22MODERNA : Lucky few hit COVID-19 vaccine jackpot for rare extra doses
AQ
01/22MODERNA : Severe allergic reactions to Moderna vaccine appear rare -CDC report
RE
01/22AstraZeneca's initial EU delivery volumes of COVID-19 vaccine to fall short
RE
01/22MODERNA : BofA Securities Adjusts Moderna PT to $140 From $130, Maintains Neutra..
MT
01/22Where Our Current Covid-19 Vaccination Rate Will Take Us
DJ
01/22Studies of South African Coronavirus Strain Raise Concerns About Immune Respo..
DJ
01/22PRESS RELEASE : BB BIOTECH AG: Vaccines leading -2-
DJ
More news
Financials (USD)
Sales 2020 512 M - -
Net income 2020 -571 M - -
Net cash 2020 2 597 M - -
P/E ratio 2020 -107x
Yield 2020 -
Capitalization 51 846 M 51 846 M -
EV / Sales 2020 96,2x
EV / Sales 2021 4,40x
Nbr of Employees 1 100
Free-Float 90,0%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 137,27 $
Last Close Price 131,02 $
Spread / Highest target 41,2%
Spread / Average Target 4,77%
Spread / Lowest Target -47,3%
EPS Revisions
Managers and Directors
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
Noubar B. Afeyan Chairman
David W. Meline Chief Financial Officer
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.25.41%51 846
LONZA GROUP AG5.34%50 271
CELLTRION, INC.-13.65%38 245
IQVIA HOLDINGS INC.3.58%35 582
SEAGEN INC.4.35%33 059
HANGZHOU TIGERMED CONSULTING CO.,LTD13.79%24 266